EODData

MEMBERSHIP REGISTER LOG IN

FRA, VM4: Vanda Pharmaceuticals Inc

06 Feb 2026
LAST:

6.000

CHANGE:
 0.30		OPEN:
6.000		HIGH:
6.000		ASK:
0.000		VOLUME:
100
CHG(%):
4.76		PREV:
6.300		LOW:
6.000		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Feb 266.0006.0006.0006.000100
05 Feb 266.3006.3006.3006.300100
04 Feb 266.6506.6506.6506.650100
03 Feb 266.4507.0006.4507.000100
02 Feb 266.2006.2006.2006.200500
30 Jan 266.4006.4006.4006.4001.4K
29 Jan 266.3006.3006.3006.3001.4K
28 Jan 266.6006.6006.6006.6001.4K
27 Jan 266.4006.4006.4006.4001.4K
26 Jan 266.6506.6506.6506.650500

PROFILE

Name:Vanda Pharmaceuticals Inc
About:Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Sector:Healthcare
Industry:Biotechnology
Address:2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037
Website:https://www.vandapharma.com
ISIN:US9216591084
LEI:529900AY8VOOQBKJ0O70

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:116.00 
Forward P/E:9.92 
PEG Ratio:9.92 
Price to Sales:1.72 
Price to Book:0.89 
Profit Margin:-0.40 
Operating Margin:-0.56 
Return on Assets:-0.12 
Return on Equity:-0.17 
Revenue:180.16M 
Shares:59.09M 
Market Cap:354.53M 

TECHNICAL INDICATORS

MA5:6.437.2%
MA10:6.457.5%
MA20:6.437.1%
MA50:5.842.7%
MA100:5.0119.8%
MA200:4.4435.1%
RSI14:45.71
WPR14:-100.00 
MTM14:-0.30
ROC14:-0.05 
ATR:0.25 
Week High:7.0016.7%
Week Low:6.000.0%
Month High:7.1519.2%
Month Low:6.0035.1%
Year High:7.6026.7%
Year Low:3.4375.0%
Volatility:35.07